rs377767391
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_020975.6(RET):c.1831T>A(p.Cys611Ser) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C611F) has been classified as Pathogenic.
Frequency
Consequence
NM_020975.6 missense
Scores
Clinical Significance
Conservation
Publications
- familial medullary thyroid carcinomaInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, G2P
- multiple endocrine neoplasia type 2AInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen, G2P
- multiple endocrine neoplasia type 2BInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Orphanet, Labcorp Genetics (formerly Invitae), ClinGen
- pheochromocytomaInheritance: AD Classification: DEFINITIVE Submitted by: G2P
- Hirschsprung disease, susceptibility to, 1Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- Haddad syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Hirschsprung diseaseInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- renal agenesis, unilateralInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- bilateral renal agenesisInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- renal agenesisInheritance: AR Classification: LIMITED Submitted by: G2P
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| RET | NM_020975.6 | c.1831T>A | p.Cys611Ser | missense_variant | Exon 10 of 20 | ENST00000355710.8 | NP_066124.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Multiple endocrine neoplasia, type 2 Pathogenic:1
This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with multiple endocrine neoplasia type 2 (PMID: 8807338, 12734540). It has also been observed to segregate with disease in related individuals. This sequence change replaces cysteine, which is neutral and slightly polar, with serine, which is neutral and polar, at codon 611 of the RET protein (p.Cys611Ser). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. This variant disrupts the p.Cys611 amino acid residue in RET. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8626834, 11331212, 20979234). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:1
PP3, PP4, PM1, PM2, PM5 -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.C611S pathogenic mutation (also known as c.1831T>A), located in coding exon 10 of the RET gene, results from a T to A substitution at nucleotide position 1831. The cysteine at codon 611 is replaced by serine, an amino acid with dissimilar properties. Multiple mutations at codon 611 have been associated with Hirschprung Disease (HSCR), Multiple Endocrine Neoplasia Type 2A (MEN2A), and Familial Medullary Thyroid Cancer (FMTC). In one study, this particular mutation was reported in a Japanese family in which the proband and his father were affected with medullary thyroid cancer, and the proband's son was affected with HSCR (Nishikawa M et al. Eur J Hum Genet. 2003 May;11(5):364-8). The American Thyroid Association Guidelines Task Force has provided recommendations for individuals with RET gene mutations (Kloos et al. Thyroid. 2009 June; 19(6):565-612). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at